Información del artÃculo
El Texto completo está disponible en PDF
Bibliografía
[1.]
F.J. Nieto.
Infections and atherosclerosis: new clues from an old hypothesis?.
Am J Epidemiol, 148 (1998), pp. 937-948
[2.]
R. Ross.
Atherosclerosis: an inflammatory disease.
N Engl J Med, 340 (1999), pp. 115-126
[3.]
N. Rifai, P.M. Ridker.
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease.
Clin Chem, 47 (2001), pp. 403-411
[4.]
G.D. Lowe, A. Rumley, P.M. Sweetnam, J.W. Yarnell, J. Rumley.
Fibrin D-dimer, markers of coagulation activation and the risk of major ischaemic heart disease in the Caerphilly study.
Thromb Haemost, 86 (2001), pp. 822-827
[5.]
G.S. Berenson, S.R. Srinivassan, W. Bao, W.P. Newman 3rd, R.E. Tracy, W.A. Wattigney.
Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study.
N Engl J Med, 338 (1998), pp. 1650-1656
[6.]
C. Napoli, C.K. Glass, J.L. Witztum, R. Deutsch, F.P. D´Armiento, W. Palinski.
Influence of maternal hypercholesterolaemia during pregnancy on progresion of early atherosclerotic lesions in childhood: Fate of Early Lessions in Children (FELIC) study.
Lancet, 354 (1999), pp. 1234-1241
[7.]
R. Ross, J.A. Glomset.
The pathogenesis of atherosclerosis.
N Engl J Med, 295 (1976), pp. 369-377
[8.]
R. Ross.
The pathogenesis of atherosclerosis. An update.
N Engl J Med, 314 (1986), pp. 488-500
[9.]
R. Virchow.
Phlogose und thrombose im Gefa system.
Gesammelte Abhandlungen zur wissenschaftliche Medizin, pp. 458-463
[10.]
Von Rokitansky K. Handbuch der pathologische anatomie. Vol 2. Wien: Braunmüller und Seidel, 1844
[11.]
J.B. Duguid.
Thrombosis as a factor in the pathogenesis of coronary atherosclerosis.
J Pathol Bacteriol, 58 (1946), pp. 207-212
[12.]
J.H. Ip, V. Fuster, L. Badimón, J. Badimón, M.B. Taubman, J.H. Chesebro.
Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation.
J Am Coll Cardiol, 15 (1990), pp. 1667-1687
[13.]
R.A. Herrmann, R.A. Malinauskas, G.A. Truskey.
Characterization of sites with elevated LDL permeability at intercostal, celiac, and iliac branches of the normal rabbit aorta.
Arterioscler Thromb, 14 (1994), pp. 313-323
[14.]
S. Glagov, C. Zarins, D.P. Giddens, D.N. Ku.
Hemodynamics and atherosclerosis: insights and perspectives gained from studies of human arteries.
Arch Pathol Lab Med, 112 (1988), pp. 1018-1031
[15.]
D.L. Fry, E.E. Herderick, D.K. Johnson.
Local intimal medial uptakes of125I albumin,125I LDL, and parenteral Evans blue dye protein complex along the aortas of normocholesterolemic minipigs as predictors of subsequent hypercholesterolemic atherogenesis.
Arterioscler Thromb, 12 (1992), pp. 1313-1328
[16.]
E. Hjelms, S. Stender.
Accelerated cholesterol accumulation in homologous arterial transplants in cholesterol fed rabbits. A surgical model to study transplantation atherosclerosis.
Arterioscler Thromb, 12 (1992), pp. 771-779
[17.]
S. Lin, C. Hong, M. Chang, B.N. Chiang, S. Chien.
Long term nicotin exposure increases aortic endothelial cell death and enhances transendothelial macromolecular transport in rats.
Arterioscler Thromb, 12 (1992), pp. 1305-1312
[18.]
I. Autio, O. Jaakkola, T. Solakivi, T. Nikkari.
Oxidized low density lipoprotein is chemotactic for arterial smooth muscle cells in culture.
FEBS Lett, 277 (1990), pp. 247-249
[19.]
J.P. Strong, C. Restrepo, M. Guzman.
Coronary and aortic atherosclerosis in New Orleans. II. Comparison of lesions by age, sex and race.
Lab Invest, 39 (1978), pp. 364-369
[20.]
V. Fuster, B. Stein, B.A. Ambrose, L. Badimón, J.J. Badimón, J.H. Chesebro.
Atherosclerotic plaque rupture and thrombosis: evolving concepts.
Circulation, 82 (1990), pp. 47-59
[21.]
P.D. Richardson, M.J. Davies, G.V.R. Born.
Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques.
Lancet, 2 (1989), pp. 941-944
[22.]
E. Falk.
Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion.
Circulation, 71 (1985), pp. 699-708
[23.]
T.M. Singh, M.H. Kadowski, S. Glacov, C.K. Zarins.
Role of fibrinopeptide B in early atherosclerotic lesion formation.
Am J Surg, 160 (1990), pp. 156-159
[24.]
H. Healy, J. Westhuyzen.
Biology and relevance of C-reactive protein in cardiovascular and renal disease.
Ann Clin Lab Sci, 30 (2000), pp. 133-143
[25.]
R.P. Tracy.
Inflammation markers and coronary heart disease.
Curr Opin Lipidol, 10 (1999), pp. 345-441
[26.]
J. Danesh, P. Whincup, M. Walker, L. Lennon, A. Thomson, P. Appleby, et al.
Low grade inflammation and coronary heart disease: prospective study and updated meta—analyses.
BMJ, 321 (2000), pp. 199-204
[27.]
G. Blake, P.M. Ridker.
Novel clinical markers of vascular wall inflammation.
Circ Res, 89 (2001), pp. 763-771
[28.]
L.E.P. Rhode, C.H. Hennekens, P.M. Ridker.
Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men.
Am J Cardiol, 84 (1999), pp. 1018-1022
[29.]
W.K. Lagrand, C.A. Visser, W.T. Hermens, H.W.M. Niessen, F.W.A. Verheugt, G.J. Wolbink, et al.
C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon?.
Circulation, 100 (1999), pp. 96-102
[30.]
S.J. Cleland, N. Sattar, J.R. Petrie, N.G. Forouhi, H.L. Elliot, J.M.C. Connell.
Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease.
Clin Sci, 98 (2000), pp. 531-535
[31.]
V. Pasceri, J.T. Willerson, E.T.H. Yeh.
Direct proinflammatory effect of C-reactive protein on human endothelial cells.
Circulation, 102 (2000), pp. 2165-2168
[32.]
S. Thompson, J. Kienast, S. Pyke, F. Haverkate, J.C. Van de Loo.
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris.
N Engl J Med, 332 (1995), pp. 635-641
[33.]
L.H. Kuller, R.P. Tracy, J. Shaten, E.N. Meilahn.
for the MRFIT Research Group. Relation of C reactive protein and coronary heart disease in the MRFIT nested case-control study.
Am J Epidemiol, 144 (1996), pp. 537-547
[34.]
P.M. Ridker, M. Cushman, M.J. Stampfer, R.S. Tracy, C.H. Hennkens.
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
N Engl J Med, 336 (1997), pp. 973-979
[35.]
P. Ridker, R. Glynn, C. Hennekens.
C reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.
Circulation, 97 (1998), pp. 2007-2011
[36.]
P.M. Ridker, C.H. Hennekens, J.F. Buring, N. Rifai.
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
N Engl J Med, 342 (2000), pp. 836-843
[37.]
T.E. Strandberg, R.S. Tilvis.
C Reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly.
Arterioscler Thromb Vasc Biol, 20 (2000), pp. 1057-1060
[38.]
K.O. Pitila, A.P. Harmoinen, J. Jokiniitty, A.I. Pasternack.
Serum C-reactive protein concentraction in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment.
Eur Heart J, 17 (1996), pp. 1345-1349
[39.]
W.L. Roberts, R. Sedrick, L. Moulton, A. Spencer, N. Rifai.
Evaluation of a four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications.
Clin Chem, 46 (2000), pp. 461-468
[40.]
H. Benamer, P.G. Steg, J. Benessiano, E. Vicaut, C. Gaultier, A. Boccara, et al.
Comparison of the prognostic value of C reactive protein and troponin T in patients with unstable angina pectoris.
Am J Cardiol, 82 (1998), pp. 845-850
[41.]
S. Tommasi, E. Carluccio, M. Bentivoglio, M. Buccolieri, M. Mariotti, M. Politano, et al.
C-reactive protein as a marker for cardiac isquemic events in the year after a first, uncomplicated myocardial infarction.
Am J Cardiol, 83 (1999), pp. 1595-1999
[42.]
C.R. Canova, C. Courtin, W.H. Reinhart.
C reactive protein (CRP) in cerebrovascular events.
Atherosclerosis, 147 (1999), pp. 49-53
[43.]
P.M. Ridker, N. Rifai, M.A. Pfeffer, F.M. Sackz, L.A. Moye, S. Goldman, et al.
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels.
Circulation, 98 (1998), pp. 839-844
[44.]
N. Sattar, M. Perera, M. Small, M.A. Lumsden.
Hormone replacement therapy and sensitive C.reactive protein concentrations in women with type-2 diabetes.
Lancet, 354 (1999), pp. 487-488
[45.]
P.M. Ridker, N. Rifai, M.A. Pfeffer, F.M. Sacks, E. Braunwald.
for the cholesterol and recurrent events (CARE) Investigators. Long-term effects of pravastatin on plasma concentraction of C-reactive protein.
Circulation, 100 (1999), pp. 230-235
[46.]
D.C. Chan, G.F. Watts, P.H.R. Barrett, L.J. Beilin, T.A. Mori.
Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity.
Clin Chem, 48 (2002), pp. 877-883
[47.]
J.A. Gómez-Gerique, E. Ros, J. Olivan, J.M. Mostaza, M. Vilardell, X. Pinto, et al.
Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
Atherosclerosis, 162 (2002), pp. 245-251
[48.]
M. Cortellaro, E. Cofrancesco, C. Boschetti, F. Cortellaro, M. Mancini, M. Mariani, et al.
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C-reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study), Fluvastatin alone and in combination tretament.
Thromb Haemost, 83 (2000), pp. 549-553
[49.]
W. Koenig.
C-reactive protein and cardiovascular risk: Has the time come for screening the general population?.
Clin Chem, 47 (2001), pp. 9-10
[50.]
P.M. Ridker.
High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
Circulation, 103 (2001), pp. 1813-1818
[51.]
H.K. Meier-Ewert, P.M. Ridker, N. Rifai, N. Price, D.F. Dinges, J.M. Mullington.
Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects.
Clin Chem, 47 (2001), pp. 426-430
[52.]
C. Kluft, P.M. De Maat.
Determination of the habitual low blood level of C-reactive protein in individuals.
Ital Heart J, 2 (2001), pp. 172-180
[53.]
W. Koenig.
C-reactive protein: risk assesment in the primary prevention of atherosclerotic disease. Has the time come for including it in the risk profile?.
Ital Heart J, 2 (2001), pp. 157-163
[54.]
R.E. Schutgens, E.U. Esseboom, F.J. Haas, H.K. Nieuwenhuis, D.H. Biesma.
Usefulness of a semiquantitative D-dimer test for the exclusion of deep venous thrombosis in outpatients.
Am J Med, 112 (2002), pp. 617-621
[55.]
M. Cushman, R.N. Lemaitre, L.H. Kuller, R.M. Psaty, E.M. Macy, A.R. Sharrett, et al.
Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study.
Arterioscler Thromb Vasc Biol, 19 (1999), pp. 493-498
[56.]
A.J. Moss, R.E. Goldstein, V.J. Marder, C.E. Sparks, D. Oakes, H. Greenberg, et al.
Thrombogenic factors and recurrent coronary events.
Circulation, 99 (1999), pp. 2517-2522
[57.]
J. Danesh, P. Whincup, M. Walker, L. Lennon, A. Thomson, P. Appelby, et al.
Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis.
Circulation, 103 (2001), pp. 2323-2327
[58.]
A.J. Lee, G.R. Fowkes, G.D. Lowe, A. Rumley.
Determinants of fibrin D-dimer in the Edinburgh Artery Study.
Arterioscler Thromb Vasc Biol, 15 (1995), pp. 1094-1097
[59.]
G.D. Lowe, J.W. Yarnell, A. Rumley, D. Bainton, P.M. Sweetnam.
C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis.
Arterioscler Thromb Vasc Biol, 21 (2001), pp. 603-610
[60.]
J.W. Yarnell, P.M. Sweetnam, A. Rumley, G.D. Lowe.
Lifestyle factors and coagulation activation markers: the Caerphilly Study.
Blood Coagul Fibrinolysis, 12 (2001), pp. 721-728
[61.]
W. Koenig, D. Rothenbacher, A. Hoffmeister, M. Griesshammer, H. Brenner.
Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study.
Arterioscler Thromb Vasc Biol, 21 (2001), pp. 1701-1705
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.